TMS vs Antidepressant Medication: When to Consider Each

Patients weighing transcranial magnetic stimulation against another antidepressant prescription often phrase the question as a choice between two competing therapies. Clinically, that framing is incorrect. TMS and antidepressant medication are not alternatives for the same situation — they sit at different points on the standard step-care ladder for major depressive disorder, and most patients who reach TMS continue their antidepressant alongside it. The useful question is not which one, but when each, and in what order. This article walks through the step-care framework psychiatry actually uses, the patient-relevant differences between the two modalities, and the specific clinical scenarios in which each is appropriate.

The standard step-care framework for major depressive disorder

The American Psychiatric Association's practice guideline for the treatment of patients with major depressive disorder describes a sequential, measurement-based approach in which treatment is escalated when an adequate trial fails to produce remission.¹ In routine outpatient psychiatry, the ladder looks roughly like this.

First line. A selective serotonin reuptake inhibitor (SSRI) or a serotonin–norepinephrine reuptake inhibitor (SNRI) — sertraline, escitalopram, venlafaxine, duloxetine, and similar agents — plus an evidence-based psychotherapy (cognitive behavioral therapy, interpersonal therapy) where indicated.¹ In the STAR*D effectiveness study, the first-step remission rate was approximately 33% on citalopram monotherapy.²

Second line. Switch antidepressant class, augment with a second agent (for example, bupropion, mirtazapine, lithium, T3, or an atypical antipsychotic with an MDD-adjunct indication), or add psychotherapy if not already in place.¹ Each additional medication step in STAR*D produced a smaller incremental gain than the one before it.²

Treatment-resistant. After two or more antidepressant trials of adequate dose and adequate duration within the current episode fail to produce remission, the depression meets the working definition of treatment-resistant depression (TRD).³ At this point, TMS therapy becomes a clinically appropriate next step.

A 2023 reanalysis of STAR*D's patient-level data using the protocol-stipulated blinded outcome measure (Pigott et al.) reported a substantially lower cumulative remission rate — closer to 35% across all four steps — than the 67% figure originally reported.⁴ The original investigators have disputed the reanalysis methodology.⁵ The exact cumulative figure is therefore a range, but the clinical implication is unchanged: a meaningful subgroup of patients does not remit on sequential medication trials alone, and serial monotherapy past two failed trials produces diminishing returns.

This is where TMS enters the framework — as the next step, not the first step and not the last step. The NeuroStar 510(k) clearance (K061053, 2008) governs the indication language used by most U.S. payers: TMS is cleared for adults with major depressive disorder who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.⁶ In other words, the clearance itself presupposes a prior antidepressant trial — TMS does not displace medication, it follows it.

How the two modalities differ — in terms that matter to patients

The two treatments differ on five dimensions that patients consistently want explained.

Mechanism. Oral antidepressants act systemically. Once absorbed, they distribute throughout the brain and the rest of the body and modulate monoaminergic neurotransmitter availability — serotonin, norepinephrine, dopamine — across the entire central nervous system and peripheral tissues. TMS acts focally. A copper coil held against the scalp generates a brief magnetic field that induces a small electrical current in a focal region of the left dorsolateral prefrontal cortex (DLPFC), roughly 2 to 3 cm in diameter.⁷ The therapeutic effect propagates from that cortical site through known network connections — most importantly to the subgenual anterior cingulate cortex, a deeper limbic node implicated in depression.⁸

Side-effect profile. Different, not "better" or "worse." SSRIs and SNRIs commonly produce gastrointestinal symptoms (nausea, loose stools), sexual side effects (decreased libido, delayed orgasm), weight change, fatigue or activation, and a subset of patients describe emotional blunting — a flattening of affective range. These effects are systemic by mechanism, not idiosyncratic. TMS side effects are local and self-limited: scalp discomfort under the coil and headache, both typically mild and improving over the first one to two weeks of treatment.⁹ Seizure is the principal rare serious adverse event, estimated at fewer than 1 in 60,000 sessions when published safety guidelines are followed.¹⁰

Time to clinical effect. Both modalities take weeks. Antidepressants typically require four to eight weeks at therapeutic dose before a definitive response judgment can be made.¹ TMS produces measurable effect over weeks as well — most patients who respond do so by the midpoint of the acute course, with the formal response assessment at the end of approximately 36 sessions.⁹ Neither modality is a same-week intervention.

Time burden. Antidepressants are taken once daily at home. A standard TMS course requires five sessions per week for six to nine weeks in the clinic, typically delivered as 19-minute iTBS sessions or 37-minute 10 Hz rTMS sessions plus coil positioning and a brief check.^{11 12} The trade is real and worth naming: TMS asks for a defined block of clinic time across roughly two months in exchange for a non-systemic mechanism and an effect that does not depend on continued daily dosing.

Cost and coverage. Generic SSRIs and SNRIs are inexpensive — typically a few dollars per month with most prescription drug coverage. TMS is expensive without insurance but is widely covered by most major commercial payers and Medicare for adults who meet TRD criteria, subject to plan-specific medical-necessity documentation and prior authorization. You can verify your coverage before any scheduling commitment.

Durability of effect. Antidepressants require ongoing daily use; discontinuation generally returns relapse risk to baseline within weeks to months. A standard acute TMS course produces an effect that can persist for months after the last session in many patients, with the option of maintenance or reintroduction sessions if symptoms recur.¹³ The two modalities therefore play different roles in the long-term plan: medication for ongoing maintenance of mood, TMS for a discrete neuroplastic intervention with a longer downstream tail.

Why most patients end up using both

In real-world practice, the modal TMS patient is on an antidepressant during the TMS course and continues that antidepressant after. The clearance language itself anticipates this: the indication is for patients who failed to achieve satisfactory improvement from prior antidepressant medication, not for patients who have discontinued it.⁶ In Carpenter and colleagues' multisite naturalistic study of 307 patients receiving TMS in routine clinical practice, the average patient had failed approximately 2.5 adequate antidepressant trials in the current episode — and most remained on a current antidepressant during treatment.⁹

Combination is the norm for two reasons. First, abruptly discontinuing an SSRI or SNRI to start TMS introduces avoidable destabilization risk and is not supported by the clearance, the trial evidence, or the clinical guidelines. Second, the two modalities act through complementary mechanisms — one systemic, one focal-cortical — and the treating psychiatrist coordinates them together. At Healing TMS, the same practice that delivers the TMS course handles the medication management strategy alongside it, so adjustments to either side of the plan are made by the same clinician.

Scenarios where each is more appropriate

These are illustrative patterns from routine practice — not a substitute for the clinical evaluation, which determines the actual recommendation in any individual case.

Antidepressant first is generally appropriate when: a patient has newly diagnosed major depressive disorder with no prior treatment history; severity is mild to moderate; there is no contraindication to first-line antidepressants; and the clinical picture does not include features (such as severe melancholia or psychotic features) that would warrant a more intensive first step.¹

TMS as the next step is appropriate when: a patient has failed two or more adequate antidepressant trials in the current episode and meets criteria for treatment-resistant depression; systemic side effects of SSRIs or SNRIs have limited the dose that can be sustained; the patient prefers a non-systemic mechanism (for example, where pregnancy planning, fertility, or sexual side effects are clinically relevant considerations); or comorbidities make first-line antidepressants clinically suboptimal at adequate dose.^{6 9}

Both simultaneously — the most common configuration in practice — when a patient meets TRD criteria, the treating psychiatrist will typically continue an antidepressant (or adjust it) and add a course of TMS, sometimes with psychotherapy in parallel. This is the configuration the trial evidence and the clearance language describe.^{6 9}

The article does not address dosing of any specific antidepressant, brand-name comparisons within the SSRI or SNRI classes, or the choice of augmentation agent — those are individual clinical decisions made with the treating psychiatrist after a complete review of history, prior trials, and comorbidities.

Key takeaways

• The framing is not "TMS vs. antidepressants." The two modalities sit at different points on the standard step-care ladder for major depressive disorder.
• First line is an SSRI or SNRI plus psychotherapy where indicated; the STAR*D first-step remission rate was approximately 33%, with diminishing returns at each subsequent medication step.^{2 4}
• TMS is the next step, not the first or the last, for adults who have failed two or more adequate antidepressant trials in the current episode — the language used in the original FDA clearance (K061053, 2008).⁶
• Side-effect profiles differ in mechanism. Antidepressant side effects are systemic; TMS side effects are local (scalp discomfort, headache) and self-limited.⁹
• Time burden differs. Antidepressants are once-daily at home; TMS is approximately five sessions per week for six to nine weeks of clinic visits.^{11 12}
• Most TMS patients remain on an antidepressant during and after the course. Combination is the norm, not the exception, and the treating psychiatrist coordinates both.⁹

For patients in Anaheim, Orange County, and the broader 30-mile radius weighing whether TMS therapy is the appropriate next step after one or more antidepressant trials, our psychiatrists conduct the candidacy evaluation and coordinate medication management within the same practice. Most patients begin by verifying insurance coverage so the clinical recommendation and the financial picture are clear in the same conversation.

Sources / Further reading